What’s Next for CAR T-Cell Therapy? Top issues for researchers and clinicians utilizing CAR T-cell therapy include: Shortening the manufacturing time and vein-to-vein time, scaling productivity, managing side effects, and …
CAR T-Cell Therapy HCP Guide – Future Implications for CAR T-Cell Therapy Read More
Costs and Payer Questions A patient-specific and complicated manufacturing process such as CAR T is expected to be costly. The cost of the first CAR T cell therapy from Novartis …
CAR T-Cell Therapy HCP Guide – The Costs Involved in CAR T-Cell Therapy Read More CAR T-Cell Therapy: A Viable Option? Chimeric antigen receptor (CAR) T-cell therapy is the first form of gene therapy approved in the U.S. CAR T-cell therapy works with the patient’s …
CAR T-Cell Therapy HCP Guide – CAR T-Cell Therapy’s Effect on the Healthcare System Read More
T-Cell Receptor Therapy: The Next Generation T cells are one type of lymphocyte important for the immune system to function properly. As with CAR T-cell therapy effect on hematologic cancers, …
CAR T-Cell Therapy HCP Guide – The Next Generation for T-Cell Receptor Therapy Read More
The Challenging Solid Tumor Microenvironment The challenging tumor microenvironment is another obstacle with CAR T-cell therapy of solid tumors. As reported by Newick and colleagues, significant hurdles include: Trafficking: CAR …
CAR T-Cell Therapy HCP Guide – Challenges: Car-T and Solid Tumors Read More
Solid Tumor Research: Ongoing CAR T-cell therapy has shown great success in hematologic malignancies, such as non-Hodgkin’s lymphoma (diffuse large B-cell lymphoma (DLBCL), follicular lymphoma), acute lymphoblastic leukemia (ALL), chronic …
CAR T-Cell Therapy HCP Guide – Solid Tumors Read More
ZUMA-3 and ZUMA-4 Trials In addition to the October 2017 approval for Non-Hodgkin lymphoma, Yescarta (axicabtagene ciloleucel) has shown impressive early results in difficult-to-treat patients with ALL. As reported in …
CAR T-Cell Therapy HCP Guide – Efficacy and Safety of Zuma Trials Read More
Use of Yescarta in Acute Lymphoblastic Leukemia Yescarta (axicabtagene ciloleucel) is also under late Phase 1 research for treatment of refractory or relapsed acute lymphoblastic leukemia (r/r ALL). ALL is …
CAR T-Cell Therapy HCP Guide – Use of Yescarta in Acute Lymphoblastic Leukemia Read More
Creating a universal CAR T agent could help avoid the lengthy and sometimes dangerous time period from apheresis of T-cells to re-infusion, which on average runs 2 to 2.5 weeks, …
CAR T-Cell Therapy HCP Guide – Is There A Universal CAR-T Cell Therapy? Read More
While side effects can be challenging, the fact remains that complete and partial remissions are impressive with CAR T-cell therapy. All eligible patients have exhausted their cancer treatment options, and …
CAR T-Cell Therapy HCP Guide – What Studies Are Ongoing With CAR T-Cell Therapy? Read More